IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
IBZM-SPECT is useful as a predictor for the responsiveness to oral L-DOPA therapy in de novo parkinsonian patients. A reduction of postsynaptic dopamine D2 receptors in de novo parkinsonian patients makes the diagnosis of Parkinson's disease rather unlikely. Normal IBZM binding does not prove the diagnosis of Parkinson's disease; however, together with a positive apomorphine test, it strongly supports the clinical diagnosis. At present the combination of IBZM-SPECT and apomorphine testing appears to be a useful procedure for selecting de novo patients for clinical trials with new anti-parkinsonian therapy.
Oertel
W H
WH
Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Germany.
Schwarz
J
J
Tatsch
K
K
Arnold
G
G
Gasser
T
T
Kirsch
C M
CM
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001058:Apomorphine; D001549:Benzamides / Q000493:pharmacokinetics*; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000187:drug effects; D065127:Dopamine D2 Receptor Antagonists; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011446:Prospective Studies; D011759:Pyrrolidines / Q000493:pharmacokinetics*; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology; D015899:Tomography, Emission-Computed, Single-Photon
D001549:Benzamides; D065127:Dopamine D2 Receptor Antagonists; D011759:Pyrrolidines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D001058:Apomorphine